| rilunermin alfa (SCB-313) / Sichuan Clover Biopharma |
ChiCTR1900025015: A Phase I Study for Evaluating the Safety, Tolerability and Pharmacokinetics of SCB-313, Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein, for the Treatment of Subjects With Peritoneal Carcinomatosis |
|
|
| Recruiting | 1 | 3 | | SCB-313 lyophilized powder needs to be reconstituted before usage. In the dose escalation phase, the designated dose of SCB-313 will be injected once per 3 days in the peritoneal cavity for 3 consecutive doses, namely D1, D4, D7, 21 days per cycle. | Beijing Shijitan Hospital Capital Medical University; Sichuan Clover Biopharmaceuticals, Inc., Sichuan Clover Biopharmaceuticals, Inc. | Peritoneal Carcitnomatosis | | | | |
ChiCTR1900024966: A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Ascites |
|
|
| Recruiting | 1 | 30 | | Intraperitoneal injection, once a day, 10mg each time (reconstituted with 500ml 0.9% sodium chloride), 1 week after single dose, continuous dose 3 times total for 1 treatment cycle | Shanghai East Hospital; Sichuan Clover Biopharmaceuticals, Inc., Sichuan Clover Biopharmaceuticals, Inc. | Malignant Ascites | | | | |
ChiCTR1900026408: A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of SCB-313, Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein, for the Treatment of Malignant Pleural Effusion |
|
|
| Recruiting | 1 | 12 | | SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation . | West China Hospitial, Sichuan University; Sichuan Clover Biopharmaceuticals, Inc., Sichuan Clover Biopharmaceuticals, Inc. | Malignant Pleural Effusion | | | | |
NCT04047771: A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis |
|
|
| Terminated | 1 | 10 | RoW | SCB-313, recombinant human TRAIL-Trimer fusion protein | Sichuan Clover Biopharmaceuticals, Inc. | Peritoneal Carcinomatosis | 05/22 | 05/22 | | |
| SCB-2019 / Sichuan Clover Biopharma |
NCT05470803: An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens |
|
|
| Not yet recruiting | 3 | 360 | RoW | AstraZeneca/Fiocruz, Pfizer/Wyeth, Clover SCB-2019 | D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, University of Oxford | COVID-19 | 12/22 | 08/23 | | |
NCT05812586: Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes. |
|
|
| Active, not recruiting | 3 | 760 | RoW | SCB-2019/Clover, AstraZeneca/Fiocruz, Pfizer/Wyeth | D'Or Institute for Research and Education, Bill and Melinda Gates Foundation | COVID-19 | 06/23 | 09/23 | | |
NCT05188677: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults |
|
|
| Completed | 3 | 1831 | RoW | Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine, CoronaVac Vaccine | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 06/23 | 06/23 | | |
NCT05926440: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults |
|
|
| Withdrawn | 3 | 600 | RoW | SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 08/23 | 08/23 | | |
NCT06567457: Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults |
|
|
| Withdrawn | 3 | | NA | SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 09/24 | 10/24 | | |
SPECTRA, NCT04672395: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 |
|
|
| Completed | 2/3 | 31454 | Europe, RoW | CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Placebo; 0.9% saline, SCB-2019 vaccine, SCB-2019 vaccine for Placebo | Clover Biopharmaceuticals AUS Pty Ltd, Coalition for Epidemic Preparedness Innovations, International Vaccine Institute | COVID-19 | 09/22 | 04/23 | | |
NCT05193279: Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age |
|
|
| Withdrawn | 2/3 | 3820 | RoW | Candidate vaccine, SCB-2019 | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 12/22 | 12/22 | | |
2020-004272-17: A controlled Phase 2/3 study of adjuvanted recombinant SARS-CoV-2 trimeric S-protein vaccine (SCB-2019) for the prevention of COVID-19 |
|
|
| Not yet recruiting | 2/3 | 30000 | Europe | SCB-2019 (CpG 1018/Alum-djuvanted SCB-2019), SCB-2019, Solution for injection | Clover Biopharmaceuticals AUS Pty Ltd, Clover Biopharmaceuticals AUS Pty Ltd | SARS-CoV-2-mediated COVID-19, COVID-19 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04954131: Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China |
|
|
| Active, not recruiting | 2 | 766 | RoW | Candidate Vaccine, SCB-2019, Placebo | Zhejiang Clover Biopharmaceuticals, Inc. | COVID-19 | 11/21 | 11/22 | | |
TP-SCB-2019001, NCT05087368: Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19) |
|
|
| Not yet recruiting | 2 | 520 | RoW | ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca), CoronaVac (Sinovac Biotech), Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover) | D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, Instituto Fernandes Figueira | Covid19 | 04/22 | 04/22 | | |
NCT05228314: Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults |
|
|
| Completed | 1 | 153 | RoW | Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant, CpG/alum adjuvant | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 09/22 | 04/23 | | |
| SCB-219M / Sichuan Clover Biopharma |
NCT05426369: A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) |
|
|
| Recruiting | 1 | 76 | RoW | Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein | Sichuan Clover Biopharmaceuticals, Inc. | Chemotherapy-induced Thrombocytopenia (CIT) | 06/25 | 06/25 | | |
| SCB-340 / Sichuan Clover Biopharma |
| No trials found |
